Enoxaparin

證據等級: L5

預測適應症: 1 個

Enoxaparin: From Venous Thromboembolism to Thrombophilia due to Protein C Deficiency (Autosomal Recessive)

One-Sentence Summary

Enoxaparin is a low molecular weight heparin (LMWH) widely used for the prevention and treatment of venous thromboembolism (VTE) and acute coronary syndromes. The TxGNN model predicts it may be effective for Thrombophilia due to Protein C Deficiency, Autosomal Recessive, with no registered clinical trials and no published literature currently available for this specific indication. The mechanistic rationale, however, is strong and well-recognised by hematology guidelines.

Quick Overview

Item	Content
Original Indication	Venous thromboembolism (DVT/PE) prevention and treatment; acute coronary syndromes
Predicted New Indication	Thrombophilia due to Protein C Deficiency, Autosomal Recessive
TxGNN Prediction Score	99.58%
Evidence Level	L4
India Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Enoxaparin is a low molecular weight heparin that exerts its anticoagulant effect by binding to and activating Antithrombin III (AT-III), which in turn strongly inhibits Factor Xa (anti-Xa activity) and, to a lesser extent, Thrombin (Factor IIa). Although detailed MOA data was not retrieved from DrugBank in this evidence pack, Enoxaparin’s pharmacology is extensively characterised in the literature: its anti-Xa to anti-IIa ratio of approximately 3.8:1 distinguishes it from unfractionated heparin and confers more predictable anticoagulant kinetics.

Autosomal recessive Protein C deficiency creates a profoundly hypercoagulable state. Protein C, once activated by thrombin bound to thrombomodulin, normally cleaves and inactivates Factor Va and Factor VIIIa, the two critical co-factors that amplify thrombin generation. Without Protein C, this brake is absent, resulting in unchecked thrombin formation and a high risk of life-threatening thrombosis in infancy. The complementary pathway is direct:

Protein C deficiency → ↑ Factor Va / VIIIa → ↑ Thrombin generation → Thrombosis ← [Enoxaparin intervenes via anti-Xa / anti-IIa inhibition]

By blocking Factor Xa upstream and suppressing Thrombin directly, Enoxaparin compensates for the lost Protein C anticoagulant activity at the downstream effector level. This mechanistic rationale is recognised in ISTH and ASH guidelines for the management of hereditary thrombophilia, where LMWH is used as a bridge or long-term maintenance therapy. It is important to note that Enoxaparin does not restore Protein C function itself; in severe homozygous neonates, Protein C Concentrate (PCC) or fresh frozen plasma (FFP) remains the primary intervention, with LMWH serving an adjunctive and prophylactic role.

Clinical Trial Evidence

Currently no related clinical trials registered for Enoxaparin in thrombophilia due to Protein C deficiency, autosomal recessive.

Literature Evidence

Currently no related literature available for this specific indication.

India Market Information

Enoxaparin is currently not marketed in India. No registered product licences were found in the regulatory database at the time of this report (data cut-off: 2026-04-04).

Safety Considerations

Drug Interactions: Enoxaparin has 174 known drug interactions in the DDInter database. The following major and selected moderate interactions are clinically most relevant:

Interacting Drug	Severity	Clinical Note
Acetylsalicylic acid (Aspirin)	Major	Combined antiplatelet + anticoagulant; significantly elevated bleeding risk
Abciximab	Major	GP IIb/IIIa inhibitor; additive haemorrhagic risk
Alteplase	Major	Thrombolytic agent; concurrent use markedly increases bleeding
Ibuprofen	Major	NSAID-mediated platelet inhibition + GI bleeding risk
Ketorolac	Major	High-risk NSAID; combination generally contraindicated
Acalabrutinib	Major	BTK inhibitor; additive bleeding risk, especially intracranial
Deferasirox	Major	Iron chelator; increased bleeding and GI adverse events
Ibritumomab tiuxetan	Major	Radioimmunotherapy; myelosuppression compounds bleeding risk
Tositumomab (I-131)	Major	Radioimmunotherapy; additive haemorrhagic risk
Trastuzumab emtansine	Major	ADC with thrombocytopenia risk; additive with anticoagulants
Dexfenfluramine	Moderate	Serotonergic agents may mildly alter platelet function
Sugammadex	Moderate	Theoretical displacement of heparin from plasma proteins
Iodide I-131 / I-123	Moderate	Monitor for altered biodistribution
Aliskiren	Moderate	Additive hypotensive / renal effects in high-risk patients
Diclofenac (topical)	Moderate	Low systemic absorption, but monitor in high-dose application

Note: Formal warnings and contraindications (e.g., active major bleeding, heparin-induced thrombocytopenia history) could not be retrieved from the package insert in this evidence pack. Please refer to the official prescribing information for the complete safety profile.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The mechanistic link between Enoxaparin and autosomal recessive Protein C deficiency thrombophilia is pharmacologically sound and complementary—Enoxaparin’s downstream inhibition of Factor Xa and Thrombin directly compensates for the absent Protein C anticoagulant brake. However, no clinical trials or indexed publications were identified for this precise indication, placing current evidence at L4 (mechanistic/preclinical reasoning only). Off-label use of LMWH in hereditary thrombophilia is guideline-acknowledged but not systematically studied under this rare disease classification.

To proceed, the following is needed:

Broader literature search: Re-query PubMed/EMBASE using broader terms (e.g., “LMWH + Protein C deficiency”, “hereditary thrombophilia + enoxaparin”) to capture evidence not indexed under the OMIM/ORDO disease name
Guideline review: Retrieve ISTH, ASH, and EHA guidelines on anticoagulation in Protein C deficiency to document current standard-of-care role of LMWH
Package insert retrieval: Download and parse Enoxaparin’s official prescribing information (FDA/EMA label) to fill the critical DG001 safety gap (warnings, contraindications)
MOA documentation: Query DrugBank API (DB01225) to formally document mechanism of action and fill DG002
Comparator assessment: Evaluate availability of Protein C Concentrate in the target market, as this determines whether Enoxaparin would serve as a primary or bridging therapy
Rare disease registry check: Search EURODIS, Orphanet, and national rare disease registries for case series or real-world data on anticoagulation strategies in this population
India registration pathway: As Enoxaparin is not currently marketed in India, assess regulatory pathway (new drug application or orphan designation) before any clinical development can be initiated
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.